FDA Grants Priority Review to Enhertu for HER2‑Positive Early Breast Cancer With Residual Disease
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab…
Continue Reading
FDA Grants Priority Review to Enhertu for HER2‑Positive Early Breast Cancer With Residual Disease
